本帖最后由 老马 于 2013-3-13 13:43 编辑
, U6 z$ Q5 Y a4 F: Q+ o/ v
8 t- ^! M y. i% {$ i健择（吉西他滨）+顺铂+阿瓦斯汀" {0 F4 p3 G2 u( W" C% @
Gemzar +Cisplatin + Avastin
, G- X7 P& ]" f8 mhttp://annonc.oxfordjournals.org/content/21/9/1804.full/ E8 i8 H, d/ M3 C
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
) Y6 ^* c) I/ r( |3 K/ Z9 PPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& N% V J$ G/ f: z# JResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
|: m+ d9 N" g5 X* }
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 945)
8 E$ o( x8 X8 ?+ y( I
华为网盘附件：
3 L5 w5 |+ @' |, e( Y. i【华为网盘】ava.JPG7 r) l9 g0 b1 S) n i9 P4 u
|
显身卡
